129 related articles for article (PubMed ID: 32916088)
1. Discovery of Covalent MKK4/7 Dual Inhibitor.
Jiang J; Jiang B; He Z; Ficarro SB; Che J; Marto JA; Gao Y; Zhang T; Gray NS
Cell Chem Biol; 2020 Dec; 27(12):1553-1560.e8. PubMed ID: 32916088
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration.
Pfaffenrot B; Klövekorn P; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jun; 218():113371. PubMed ID: 33794385
[TBL] [Abstract][Full Text] [Related]
3. Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.
Chen D; Wang W; Qin JJ; Wang MH; Murugesan S; Nadkarni DH; Velu SE; Wang H; Zhang R
Curr Cancer Drug Targets; 2013 Jul; 13(6):651-60. PubMed ID: 23607596
[TBL] [Abstract][Full Text] [Related]
4. Requirements for PKC-augmented JNK activation by MKK4/7.
Lopez-Bergami P; Ronai Z
Int J Biochem Cell Biol; 2008; 40(5):1055-64. PubMed ID: 18182317
[TBL] [Abstract][Full Text] [Related]
5. A Protoberberine derivative HWY336 selectively inhibits MKK4 and MKK7 in mammalian cells: the importance of activation loop on selectivity.
Kim N; Park J; Gadhe CG; Cho SJ; Oh Y; Kim D; Song K
PLoS One; 2014; 9(4):e91037. PubMed ID: 24759688
[TBL] [Abstract][Full Text] [Related]
6. Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7).
Wolle P; Engel J; Smith S; Goebel L; Hennes E; Lategahn J; Rauh D
J Med Chem; 2019 Jun; 62(11):5541-5546. PubMed ID: 31083997
[TBL] [Abstract][Full Text] [Related]
7. MKK4 Inhibitors-Recent Development Status and Therapeutic Potential.
Katzengruber L; Sander P; Laufer S
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108658
[TBL] [Abstract][Full Text] [Related]
8. From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4).
Klövekorn P; Pfaffenrot B; Juchum M; Selig R; Albrecht W; Zender L; Laufer SA
Eur J Med Chem; 2021 Jan; 210():112963. PubMed ID: 33199152
[TBL] [Abstract][Full Text] [Related]
9. MKK4 activates non-canonical NFκB signaling by promoting NFκB2-p100 processing.
Kim JS; Kim EJ; Kim HS; Kurie JM; Ahn YH
Biochem Biophys Res Commun; 2017 Sep; 491(2):337-342. PubMed ID: 28733031
[TBL] [Abstract][Full Text] [Related]
10. Differential requirement of MKK4 and MKK7 in JNK activation by distinct scaffold proteins.
Zou H; Li Q; Lin SC; Wu Z; Han J; Ye Z
FEBS Lett; 2007 Jan; 581(2):196-202. PubMed ID: 17187786
[TBL] [Abstract][Full Text] [Related]
11. Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor.
Shraga A; Olshvang E; Davidzohn N; Khoshkenar P; Germain N; Shurrush K; Carvalho S; Avram L; Albeck S; Unger T; Lefker B; Subramanyam C; Hudkins RL; Mitchell A; Shulman Z; Kinoshita T; London N
Cell Chem Biol; 2019 Jan; 26(1):98-108.e5. PubMed ID: 30449673
[TBL] [Abstract][Full Text] [Related]
12. The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7.
Haeusgen W; Herdegen T; Waetzig V
Eur J Cell Biol; 2011; 90(6-7):536-44. PubMed ID: 21333379
[TBL] [Abstract][Full Text] [Related]
13. Diverse physiological functions of MKK4 and MKK7 during early embryogenesis.
Asaoka Y; Nishina H
J Biochem; 2010 Oct; 148(4):393-401. PubMed ID: 20801953
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4.
Kircher T; Pantsar T; Oder A; Peter von Kries J; Juchum M; Pfaffenrot B; Kloevekorn P; Albrecht W; Selig R; Laufer S
Eur J Med Chem; 2021 Jan; 209():112901. PubMed ID: 33092905
[TBL] [Abstract][Full Text] [Related]
15. Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.
Wolle P; Hardick J; Cronin SJF; Engel J; Baumann M; Lategahn J; Penninger JM; Rauh D
J Med Chem; 2019 Mar; 62(5):2843-2848. PubMed ID: 30768270
[TBL] [Abstract][Full Text] [Related]
16. Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.
Vander Griend DJ; Kocherginsky M; Hickson JA; Stadler WM; Lin A; Rinker-Schaeffer CW
Cancer Res; 2005 Dec; 65(23):10984-91. PubMed ID: 16322247
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship study of THZ531 derivatives enables the discovery of BSJ-01-175 as a dual CDK12/13 covalent inhibitor with efficacy in Ewing sarcoma.
Jiang B; Jiang J; Kaltheuner IH; Iniguez AB; Anand K; Ferguson FM; Ficarro SB; Seong BKA; Greifenberg AK; Dust S; Kwiatkowski NP; Marto JA; Stegmaier K; Zhang T; Geyer M; Gray NS
Eur J Med Chem; 2021 Oct; 221():113481. PubMed ID: 33945934
[TBL] [Abstract][Full Text] [Related]
18. Filamin associates with stress signalling kinases MKK7 and MKK4 and regulates JNK activation.
Nakagawa K; Sugahara M; Yamasaki T; Kajiho H; Takahashi S; Hirayama J; Minami Y; Ohta Y; Watanabe T; Hata Y; Katada T; Nishina H
Biochem J; 2010 Mar; 427(2):237-45. PubMed ID: 20156194
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for producing selective MAP2K7 inhibitors.
Murakawa Y; Valter S; Barr H; London N; Kinoshita T
Bioorg Med Chem Lett; 2020 Nov; 30(22):127546. PubMed ID: 32931911
[TBL] [Abstract][Full Text] [Related]
20. Purification, auto-activation and kinetic characterization of apoptosis signal-regulating kinase I.
Pleinis JM; Davis CW; Cantrell CB; Qiu DY; Zhan X
Protein Expr Purif; 2017 Apr; 132():34-43. PubMed ID: 28082061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
